Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: A phase II study of the european organization for research and treatment of cancer lung cancer cooperative group (EORTC 08955)

Journal of Clinical Oncology

Volumn 18, Issue 14, 2000, Pages 2658-2664

  Van Zandwijk, N ^a   Smit, E F ^a   Kramer, G W P ^a   Schramel, F ^a   Gans, S ^a   Festen, J ^a   Termeer, A ^a   Schlosser, N J J ^a   Debruyne, C ^a   Curran, D ^a   Giaccone, G ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 0033941848     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.14.2658     Document Type: Article

References (24)

1. Lilenbaum RC, Green M: Multimodality therapy for non-small cell lung cancer. Oncology 8:25-31, 1994
2. Martini N, Kris MG, Flehinger BJ, et al: Preoperative chemotherapy for stage IIIa (N2) lung cancer: The Sloan-Kettering experience with 136 patients. Ann Thorac Surg 55:1365-1373, 1993
3. Depierre A, Milleron B, Moro D, et al: Phase III trial of neo-adjuvant chemotherapy (NCT) in resectable stage I (except T1N0), II, IIIa non-small cell lung cancer (NSCLC): The French experience. Proc Am Soc Clin Oncol 18:465a, 1999 (abstr 1792)
4. Rosell R, Gomez-Codina J, Camps C, et al: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 330:153-158, 1994
5. Roth JA, Fossella F, Komaki R, et al: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 86:673-680, 1994
6. Pass HI, Pogrebniak HW, Steinberg SM, et al: Randomized trial of neoadjuvant therapy for lung cancer: Interim analysis. Ann Thorac Surg 53:992-998, 1992
7. American Society of Clinical Oncology: Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer: Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15:2996-3018, 1997
8. Luud B, Kristjanson PEG, Hansen HH: Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 19:45-55, 1994
9. Bergman AM, Ruiz van Haperen VWT, Veerman G, et al: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2:521-530, 1996
10. Peters GJ, Ruiz van Haperen VWT, Bergman AM, et al: Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 23:16-24, 1996
11. Crinò L, Scagliotti G, Marangolo M, et al: Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 15:297-303, 1997
12. Abratt RP, Bezwoda WR, Goedhals L, et al: Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 15:744-749, 1997
13. Sandler A, Nemunaitis J, Dehnam C, et al: Phase III study of cisplatin with or without gemcitabine in patients with advanced NSCLC. Proc Am Soc Clin Oncol 17:454, 1998 (abstr 1747)
14. Cardenal F, Paz López-Cabrerizo M, Antón A, et al: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 17:12-18, 1999
15. Crinò L, Conte P, De Marinis F, et al: A randomized trial of gemcitabine cisplatin versus mitomycin, ifosfamide and cisplatin (MIC) in advanced non-small cell lung cancer (NSCLC): A multicenter phase III study. Proc Am Soc Clin Oncol 17:455, 1998 (abstr 1750)
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
17. Lynch TJ: Treatment of stage III non-small-cell lung cancer. ASCO Educational Book, Spring:265-275, 1998
18. Shepherd FA, Anglin G, Abratt R, et al: Influence of gemcitabine (GEM) and cisplatin (CP) schedule on response and survival in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17:472a, 1998 (abstr 1816)
19. Abratt RP, Sandler A, Crinò L: Combined cisplatin and gemcitabine for non-small cell lung cancer: Influence of scheduling on toxicity and drug delivery. Semin Oncol 25:35-43, 1998
20. Raach M, Fandara DR, Yuo M-S, et al: Radiation pneumonitis following combined modality therapy for lung cancer: Analysis of prognostic factors. J Clin Oncol 13:2606-2612, 1995
21. Goor C, Scalliet P, Van Meerbeeck J, et al: A phase II study combining gemcitabine and radiotherapy in stage III NSCLC. Ann Oncol 7:S101, 1996 (suppl 5) (abstr)
22. Vokes EE, Leopols KA, Herndon JE, et al: A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy and concomitant chemoradiotherapy for unresectable stage III non-small cell lung cancer (NSCLC) (CALGB study 9431). Proc Am Soc Clin Oncol 18:459a, 1999 (abstr 1771)
23. Albain KS, Rusch VW, Crowley JJ, et al: Concurrent cisplatin/ etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13:1880-1892, 1995
24. Albain KS: Induction chemotherapy with or without radiation followed by surgery in stage III non-small cell lung cancer: Update and perspectives. Oncology 11:S51-S57, 1997 (suppl 9)